Drug intelligence / Profile preview

minocycline + ethylenediaminetetraacetic acid

Development stage
Phase 4
Lead developer
Citius Pharmaceuticals
Modality
Small Molecules
Administration
Intracatheter
01

Overview

A combination antimicrobial and anticoagulant lock solution used primarily to prevent catheter-related infections. This combination leverages the antibiotic properties of minocycline with the chelating and biofilm-disrupting capabilities of EDTA. **Composition and Mechanism of Action** M-EDTA combines two active components: 1. **Minocycline**: A tetracycline antibiotic that blocks bacterial protein synthesis by binding to the 30S ribosomal subunit, effective against both gram-positive and gram-negative bacteria. 2. **EDTA (Ethylenediaminetetraacetic acid)**: A potent calcium chelating agent that: - Disrupts bacterial and fungal cell membranes - Destroys biofilm formation and structure - Provides anticoagulant activity comparable to heparin. The combination works synergistically - EDTA disrupts the biofilm matrix by chelating calcium (an essential component of biofilm structure), allowing minocycline to penetrate and exert its antimicrobial effects against embedded microorganisms. **Efficacy** Clinical studies have demonstrated significant benefits: - No port infections occurred in patients using M-EDTA in a prospective cohort study of children with cancer, compared to 10 infections in control patients using heparin. - A randomized study showed infection incidence of 20.8% with M-EDTA versus 73.1% with heparin in pediatric cancer patients. - M-EDTA reduced catheter-related infection and colonization risk by ninefold in hemodialysis patients. **Antimicrobial Spectrum** Demonstrated activity against: - Methicillin-sensitive and methicillin-resistant staphylococci - Gram-negative bacteria including *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia* - *Candida* species, including drug-resistant strains. Effective against microorganisms embedded in biofilms. **Safety Profile** Appears to have a favorable safety profile with no reported thrombotic events or significant adverse events in clinical studies.

Other names
M-EDTAminocycline-EDTAminocycline-ethylenediaminetetraacetate
02

Targets

Bacterial Ribosome

Beyond the preview

Go deeper on minocycline + ethylenediaminetetraacetic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on minocycline + ethylenediaminetetraacetic acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call